Aligos Therapeutics announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective September 24, 2024. In this role, Dr. Achneck will lead the company's global clinical development efforts. He will also serve as a member of Aligos' Senior Leadership Team.
Dr. Achneck's appointment is significant as Aligos Therapeutics advances its clinical pipeline. His leadership is expected to be instrumental in guiding the development of therapies for liver and viral diseases. This includes key candidates like ALG-000184 for chronic HBV and ALG-055009 for MASH.
The addition of a Chief Medical Officer with global clinical development experience strengthens the company's executive team. This move supports the strategic goal of improving patient outcomes through best-in-class therapies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.